Atomoxetine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Drug reference
dacomitinib
EGFR inhibitor · null
EGFR inhibitornullATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
- AtomoxetineSevereDatabaseDDInter
- BrexpiprazoleSevereDatabaseDDInter
- DeutetrabenazineSevereDatabaseDDInter
- DexlansoprazoleSevereDatabaseDDInter
Mechanism
Dacomitinib inhibits the epidermal growth factor receptor (EGFR) in lung cancers with specific EGFR mutations (deletion of exon 19 or L858R mutation).
Indications
lung NSCLC (EGFR deletion of exon 19 or L858R mutation)first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations
Pharmacokinetics
Half-life
70 h
Metabolism
hepatic metabolism (main route)
Side effects
Common
diarrheaskin rashes
Pregnancy & lactation
Pregnancy
X
Drug interactions
Brexpiprazole
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Deutetrabenazine
Severe
Database
Clinical effect not specified
Source: DDInter
Dexlansoprazole
Severe
Database
Clinical effect not specified
Source: DDInter
Eliglustat
Severe
Database
Clinical effect not specified
Source: DDInter
Esomeprazole
Severe
Database
Clinical effect not specified
Source: DDInter
Iloperidone
Severe
Database
Clinical effect not specified
Source: DDInter
Lansoprazole
Severe
Database
Clinical effect not specified
Source: DDInter
Oliceridine
Severe
Database
Clinical effect not specified
Source: DDInter
Omeprazole
Severe
Database
Clinical effect not specified
Source: DDInter
Pantoprazole
Severe
Database
Clinical effect not specified
Source: DDInter
Pexidartinib
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about dacomitinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team